Last update July 11, 2023

Darunavir (DRV)

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

HIV protease inhibitor antiviral. Used, alone or boosted with Cobicistat or Ritonavir and associated with other antivirals, in the treatment of HIV/AIDS (Navarro 2016). It has been used experimentally in the treatment of coronavirus infection COVID-19 (SEFH 2020). Oral administration in one or two daily doses.

It is excreted in breast milk in clinically insignificant amounts (Aebi 2022) and no problems have been observed in infants whose mothers took it. (Prestile 2022)

The plasma levels of these infants were very low or below the limit of detection. (Aebi 2022)

Possible side effects are rare and, in general, of mild-moderate severity: diarrhoea, nausea, rash,... (Navarro 2016)

"Individuals with HIV who are on ART with a sustained undetectable viral load and who choose to breastfeed should be supported in this decision". (Panel 2022 p ix)


See below the information of these related products:

Alternatives

We do not have alternatives for Darunavir (DRV) since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Darunavir (DRV) is also known as


Darunavir (DRV) in other languages or writings:

Group

Darunavir (DRV) belongs to this group or family:

Tradenames

Main tradenames from several countries containing Darunavir (DRV) in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 37; ( + ritonavir = 82 ) %
Molecular weight 548 daltons
Protein Binding 95 %
VD 1.2 - 3.14 l/Kg
pKa 11.4 -
Tmax 2.5 - 4 hours
15 hours
Theoretical Dose 0.047 mg/Kg/d
Relative Dose 0.36 %

References

  1. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Department of Health and Human Services. 2023 Consulted on June 16, 2023 Abstract Full text (link to original source)
  2. Aebi-Popp K, Kahlert CR, Crisinel PA, Decosterd L, Saldanha SA, Hoesli I, Martinez De Tejada B, Duppenthaler A, Rauch A, Marzolini C; Swiss Mother and Child HIV Cohort Study (SHCS).. Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study. J Antimicrob Chemother. 2022 Nov 28;77(12):3436-3442. Consulted on Dec. 16, 2022 Abstract Full text (link to original source)
  3. Prestileo T, Adriana S, Lorenza DM, Argo A. From Undetectable Equals Untransmittable (U=U) to Breastfeeding: Is the Jump Short? Infect Dis Rep. 2022 Mar 25;14(2):220-227. Consulted on April 19, 2022 Abstract Full text (link to original source)
  4. SEFH - Sociedad Española de Farmacia Hospitalaria. Procedimientos de farmacia hospitalaria para la gestión del tratamiento con antivirales en la enfermedad por el nuevo coronavirus sars-cov-2 (COVID-19). Recomendaciones de la Sociedad Española de Farmacia Hospitalaria. None 2020 Full text (in our servers)
  5. AEMPS-Reddy. Darunavir. Ficha técnica. 2018 Full text (in our servers)
  6. Navarro J, Curran A. Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS. HIV AIDS (Auckl). 2016 Oct 31;8:175-182. eCollection 2016. Review. Abstract
  7. EMA - Jansen C. Darunavir-Cobicistat (Rezolsta). Ficha técnica. 2014 Full text (in our servers)

Total visits

2,969

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM